

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

UPDATE ANNOUNCEMENT

**CONNECTED TRANSACTION IN RELATION TO
THE DISPOSAL OF 30.0704% EQUITY INTEREST IN THE TARGET COMPANY**

Reference is made to the announcement of CSPC Pharmaceutical Group Limited (the “**Company**”) dated 26 February 2026 in respect of, among other things, the disposal of 30.0704% equity interest in Beijing Guoxin Huijin Co., Ltd.* (北京國新匯金股份有限公司) (the “**Announcement**”). Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board is pleased to announce that the Disposal has been approved by the Vendor’s shareholders at the shareholders’ meeting of the Vendor convened today. Accordingly, the Disposal will proceed to completion in accordance with the terms and conditions of the Equity Transfer Agreement as disclosed in the Announcement.

By Order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 8 April 2026

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Dr. CAI Lei, Mr. WEI Qingjie, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping, Mr. QU Zhiyong and Mr. ZHANG Yiwei as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.

* *For identification purposes only*